Expression of Integrin AlphaVbeta3 in Pancreatic Carcinoma: Relation to MMP-2 Activation and Lymph Node Metastasis
Overview
Authors
Affiliations
Introduction: Overexpression of integrin alphaVbeta3 had been demonstrated in various tumors. Studies have suggested that elevated levels of integrin alphaVbeta3 in melanoma cells are deeply involved in the mechanism of increased melanoma invasiveness.
Aims: To examine the expression of integrin alphaVbeta3 in pancreatic carcinoma and to evaluate the correlation between integrin expression accompanied by MMP-2 activation and clinicopathologic factors.
Methodology: Integrin alphaVbeta3 specific antibody LM-609 was used for immunochemical analysis, and intracellular localization was determined in human pancreatic cancer cell lines cultured on vitronectin coating. Fifty pancreatic adenocarcinomas analyzed immunohistochemically and 26 frozen samples were analyzed gelatin-zymographically.
Results: Two of three pancreatic cancer cell lines demonstrated integrin alphaVbeta3 immunofluorescence with a membranous pattern, and 29 of 50 pancreatic carcinomas showed positive immunostaining of tumor cells. There was no significant correlation between integrin alphaVbeta3 expression and tumor size, tumor grade, or peripancreatic invasion. However, primary tumors with lymph node metastasis featured significantly higher expression of integrin alphaVbeta3 than those without node metastasis. Tumors with high integrin alphaVbeta3 expression showed significantly higher MMP-2 activation ratios than did tumors with low expression.
Conclusion: Expression analysis in pancreatic cancer tissue demonstrated involvement of alphaVbeta3 integrin in lymph node metastasis rather than peripancreatic invasion. MMP-2 activation is linked, at least in part, to the expression of integrin alphaVbeta3 of pancreatic cancer cells.
Yoshimoto M, Washiyama K, Ohnuki K, Doi A, Inokuchi M, Kojima M Pharmaceutics. 2025; 17(1).
PMID: 39861661 PMC: 11768328. DOI: 10.3390/pharmaceutics17010009.
Yoshimoto M, Hayakawa T, Yamaguchi M, Kimura S, Fujii H PLoS One. 2024; 19(9):e0310984.
PMID: 39316565 PMC: 11421790. DOI: 10.1371/journal.pone.0310984.
Laney V, Hall R, Yuan X, Hampson E, Halle A, Yeung G Pharm Res. 2024; 41(9):1811-1825.
PMID: 39198318 PMC: 11436418. DOI: 10.1007/s11095-024-03762-7.
Expression of integrin αβ in medullary thyroid carcinoma.
de Vries L, Lodewijk L, Pijnappel E, van Diest P, Schepers A, Bonenkamp H Future Oncol. 2024; 20(27):2015-2022.
PMID: 39101553 PMC: 11497997. DOI: 10.1080/14796694.2024.2376511.
Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.
Gu X, Minko T Cancers (Basel). 2024; 16(8).
PMID: 38672671 PMC: 11048786. DOI: 10.3390/cancers16081589.